Prediction of interindividual differences in hepatic functions and drug sensitivity by using human iPS-derived hepatocytes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 47, 2014, Pages 16772-16777

  Takayama, Kazuo ^a,b   Morisaki, Yuta ^a   Kuno, Shuichi ^a   Nagamoto, Yasuhito ^a,b   Harada, Kazuo ^a   Furukawa, Norihisa ^a   Ohtaka, Manami ^c   Nishimura, Ken ^d   Imagawa, Kazuo ^a,b,d   Sakurai, Fuminori ^a   Tachibana, Masashi ^a   Sumazaki, Ryo ^d   Noguchi, Emiko ^d   Nakanishi, Mahito ^c   Hirata, Kazumasa ^a   Kawabata, Kenji ^a,b   Mizuguchi, Hiroyuki ^a,b  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^c NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^d UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

CYP2D6; Hepatocyte; Human iPS cells; Personalized drug therapy; SNP

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ASIALOGLYCOPROTEIN RECEPTOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; KRUPPEL LIKE FACTOR 4; OCTAMER TRANSCRIPTION FACTOR 4; STAGE SPECIFIC EMBRYO ANTIGEN 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; CYTOCHROME P450;

ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; LIVER CELL; LIVER FUNCTION; NUCLEAR REPROGRAMMING; NUCLEOTIDE SEQUENCE; PLURIPOTENT STEM CELL; PREDICTION; SINGLE NUCLEOTIDE POLYMORPHISM; CYTOLOGY; DRUG EFFECTS; ENZYMOLOGY; FLOW CYTOMETRY; LIVER; LIVER FUNCTION TEST; METABOLISM;

IPS;

CELL DIFFERENTIATION; CYTOCHROME P-450 ENZYME SYSTEM; FLOW CYTOMETRY; HEPATOCYTES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LIVER; LIVER FUNCTION TESTS;

EID: 84912567134     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1413481111     Document Type: Article

References (15)

1. Takayama K, et al. (2012) Efficient generation of functional hepatocytes from human embryonic stem cells and induced pluripotent stem cells by HNF4α transduction. Mol Ther 20(1):127-137.
2. Medine CN, et al. (2013) Developing high-fidelity hepatotoxicity models from pluripotent stem cells. Stem Cells Transl Med 2(7):505-509.
3. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol Sci 25(4): 193-200.
4. Ingelman-Sundberg M (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482(1-2): 11-19.
5. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 48(11):689-723.
6. Borges S, et al. (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61-74.
7. Bakke OM, Manocchia M, de Abajo F, Kaitin KI, Lasagna L (1995) Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974. through 1993: A regulatory perspective. Clin Pharmacol Ther 58(1):108-117.
8. Lin T, et al. (2009) A chemical platform for improved induction of human iPSCs. Nat Methods 6(11):805-808.
9. Polo JM, et al. (2010) Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat Biotechnol 28(8):848-855.
10. Takayama K, et al. (2013) Long-term self-renewal of human ES/iPS-derived hepatoblast- like cells on human laminin 111-coated dishes. Stem Cell Reports 1(4):322-335.
11. McDonald MG, Rettie AE (2007) Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: Formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 20(12):1833-1842.
12. Kaufmann P, et al. (2005) Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 41(4):925-935.
13. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5(1):6-13.
14. Spina E, et al. (1997) Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study. Eur J Clin Pharmacol 51(5):395-398.
15. Nishimura K, et al. (2011) Development of defective and persistent Sendai virus vector: A unique gene delivery/expression system ideal for cell reprogramming. J Biol Chem 286(6):4760-4771.